<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

News

External stories on biodesix

Posts in: Veristrat

CGTV: Biodesix, Bioyong, and Lung Cancer Testing in China—Watch the Video

CGTV (China Television) story on Biodesix's agreement with Bioyong, and why lung cancer tests are needed in China

GenomeWeb: Biodesix Receives Two Positive Coverage Decisions for Veristrat

GenomeWeb story: Biodesix receives two positive coverage decisions for VeriStrat

AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress

Results from a analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.

Biodesix’s VeriStrat Test for Cancer Treatment Passes Phase 3 Trial (Xconomy)

Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.

Putting Lung Cancer in the Bullseye (Breakthroughs)

Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.

Biodesix Feels the Buzz at BIO2012 (FierceBiomarkers)

Biodesix’s business model is based on two strands–clinical diagnostics and companion diagnostics; Tests based on the presence or absence of a biomarker.

Charting a Course for Progress Institute of Medicine Report Calls for Rigor and Standardization (The Burrill Report)

Biodesix's Jeffrey Bojar discusses Evolution of Translational Omics: Lessons Learned and the Path Forward and the rigorous framework it provides.

Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)

Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)

Biodesix Targeting Pharma for VeriStrat (GenomeWeb)

Biodesix is looking to forge pharmaceutical partnerships to increase adoption of the test Veristrat.

CBSA BioBreakfast Focuses on Two CO Success Stories of 2009 (Rocky Radar)

CBSA's May BioBreakfast allowed two of Colorado's 2009 Bioscience success stories to share their stories. First up was Biodesix, in the diagnostic space.

1 2 Last